JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company
Company advancing ZB-168, an anti-IL7Rα monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma enterprise value of $215 million Total gross proceeds of up to $189 million of which up to $139 million is from the cash held in trust (assuming … [Read more…]